CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 665 enrolled
Drug / intervention
Eprosartan +3 moredrug
Likely dose
Eprosartan 450 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01631227
NCT01631227Phase 3Completed
CompareCT.gov

A Prospective, Randomized Double-blind Parallel Group Study to Compare the Effect of Eprosartan and Eprosartan Mesylate on Blood Pressure in Subjects With Mild to Moderate Essential Hypertension

Abbott·interventional·Posted Jun 29, 2012·Updated Jul 25, 2014

In Brief

A Phase 3 clinical trial evaluating Eprosartan, Eprosartan Mesylate, and 2 other interventions for Essential Hypertension. Completed, enrolled 665 participants across 38 sites in 3 countries.

Detailed Summary

Aim of this study is to compare the blood pressure lowering effect of a new drug formulation of eprosartan. Eprosartan belongs to a class of blood pressure lowering agents used worldwide since years with proven efficacy. The new formulation is compared to the currently marketed eprosartan tablet. Equivalent efficacy in blood pressure lowering effects should be demonstrated.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsEssential Hypertension
CountriesGermany, Russia, United Kingdom
CollaboratorsQuintiles, Inc., Synexus, author! et al. BV

Timeline

Phase 3CompletedFinished
20132014201520162017201820192020202120222023202420252026
First PostedJun 29, 2012
Enrollment StartJun 1, 2012
Primary CompletionApr 1, 2013
TodayJul 2, 2026
Enrollment to primary: 10 monthsPosted 14.0 years ago

Interventions

Eprosartandrug

Eprosartan 450 mg

Eprosartan Mesylatedrug

Eprosartan mesylate 600 mg

Placebo Eprosartan mesylatedrug

Placebo Eprosartan mesylate

Placebo Eprosartandrug

Placebo Eprosartan